Clinical Trials

36 enrolled

Carcinoma, Hepatocellular

NCT04721132 2026-03-05

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

16 enrolled

Carcinoma, Hepatocellular

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

40 enrolled

HCC

NCT05681039 2026-03-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

29 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06830694 2026-02-23

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Small Cell Lung Carcinoma

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

19 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

4 enrolled

Tumor-Agnostic

Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03896074 2026-02-09

BEAT

206 enrolled

Non-small-cell Lung Cancer Patients

NCT02525757 2026-02-04

MPDL3280A With Chemoradiation for Lung Cancer

52 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06254911 2026-01-27

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Phase 2 Suspended

20 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT04958811 2026-01-26

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

29 enrolled

Lung Neoplasms

NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2 Terminated

3 enrolled 12 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

46 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05152472 2026-01-08

ATEZOGIST

110 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

LymphoidOther hematologic neoplasm

70 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06690840 2026-01-05

AZALEA

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

100 enrolled

Lung Neoplasms

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

37 enrolled

Inflammatory Breast Neoplasms

NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

28 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT03483012 2025-12-09

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

6 enrolled 19 charts

Breast Neoplasms

NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

27 enrolled

Cholangiocarcinoma

NCT04276376 2025-12-01

ARIANES

Phase 2 Terminated

130 enrolled

Other solid neoplasm

Solid Tumor

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT01898117 2025-11-26

Triple-B

304 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

48 enrolled

Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

NCT07239245 2025-11-25

ATTACH

30 enrolled

Carcinoma, Hepatocellular

NCT07049848 2025-11-20

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma